Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Toremifene: Evidence, Mechanism and Scope
2026-10-15
A source-bounded overview of Toremifene as a second-generation selective estrogen-receptor modulator, distinguishing the supplier’s documented product claims from identity-matched research evidence and explaining what the reported Ac-1 cell-growth IC50 can—and cannot—establish.
Sodium Orthovanadate: Mechanism and Evidence Boundaries
2026-10-14
Sodium Orthovanadate (Na3VO4) is described by APExBIO as a broad, reversible inhibitor relevant to protein tyrosine phosphatases, alkaline phosphatase, ATPases, and selected metabolic enzymes. Its principal interpretive value is as a phosphorylation-state-preservation reagent, but the available product description is not an identity-matched research study and does not establish potency, selectivity, cellular performance, or outcome statistics.
What P. vivax Epitope Study Shows for Surveillance
2026-10-14
A 2026 study identified several conserved Plasmodium vivax B-cell epitopes with promising species-discriminating performance and one candidate associated with asymptomatic infection. Its findings support further validation of serological surveillance markers, but do not establish a clinical diagnostic. TMB is relevant only as a possible signal-generation concept: the supplied study does not identify TMB or APExBIO as part of the reported testing.
Comparing Claustrum Organization Across Mammals
2026-10-13
A comparative study asks whether molecular and anatomical features can identify conserved claustrum subdivisions across mammals. Its reported cross-species gene-expression patterns support shared organizational principles, but the descriptive design does not establish functional equivalence, causal mechanisms, or direct relevance to human disease.
BAY-826 and Retinal Neurovascular Signaling
2026-10-13
The supplied 2026 study supports a Müller-cell-mediated link between angiopoietin signaling, PEDF production, and retinal neuron survival in cell-based models. It does not establish that BAY-826 was used, that the compound targets Tie-2 or PI3K/Akt, or that it improves retinal survival. The compound’s reported potency and research positioning therefore remain product-level claims rather than findings from the cited retinal study.
BENPs and FLASH-RT: What the Evidence Shows
2026-10-12
A 2026 preclinical study reports that functionalized EGCG nanoparticles enhanced tumor effects when combined with FLASH radiotherapy in a 4T1 mouse model. The findings are mechanistically suggestive but remain limited by model scope, incomplete translational evidence, and the interpretive boundaries of γ-H2AX as a DNA damage biomarker.
What SAN–Plexus Assembloids Show
2026-10-12
The cited 2026 study presents human pluripotent-stem-cell-derived sinoatrial node–cardiac plexus assembloids as a model of neuro-cardiac control. Its findings support an association between innervation, pacemaker maturation, and PSAP–GPR37 signaling, while remaining limited by the in vitro nature of the system and the condensed evidence available.
Ferrostatin-1 (Fer-1): Mechanism and Evidence
2026-10-11
Ferrostatin-1 (Fer-1) is a research tool that suppresses lipid peroxidation associated with ferroptosis. Its strongest use is mechanistic interpretation of ferroptosis assays, while vendor-reported potency and cross-pathway activity require assay-specific validation.
LY294002 in PI3K Signaling: Research Context
2026-10-10
A source-grounded overview of LY294002 research, focusing on PI3K/AKT pathway interpretation, periostin regulation in HER2-positive breast cancer, evidence strength, conceptual applications, and limitations of pharmacological pathway inhibition.
Sodium Ascorbate in Cancer Research: Evidence Review
2026-10-09
Sodium Ascorbate, a mineral salt of ascorbic acid, is discussed here as a preclinical research subject rather than a proven cancer therapy. Supplier-reported redox and tumor-model findings are compared with a separate ESCC immunotherapy-biomarker study, highlighting evidence gaps, provenance limits, and the risks of extrapolating across disease models.
3-Methyladenine in STING–Autophagy Research
2026-10-09
Explore how 3-Methyladenine can inform interpretation of STING–autophagy signaling in diabetic cardiomyopathy research. This article distinguishes pharmacological pathway perturbation from causal evidence and explains the strengths and limitations of the A8353 research product.
Meropenem Trihydrate: Five Evidence Questions
2026-10-08
A source-grounded overview of how metabolomics can illuminate carbapenem resistance, what the current evidence shows, and where findings involving Meropenem trihydrate and carbapenemase-producing Enterobacterales should not be generalized.
BV6 as an IAP Antagonist: Evidence and Limits
2026-10-08
A source-grounded overview of BV6 research, including its proposed IAP-antagonist mechanism, cancer-model applications, evidence provenance, and limitations separating supplier-reported claims from peer-reviewed or preprint findings.
Azathramycin A: Evidence for TB Research
2026-10-07
Azathramycin A is a macrolide antibiotic research tool for examining ribosome-mediated protein synthesis inhibition in tuberculosis studies. This evidence-focused guide connects compound provenance, matrix effects, PK/PD interpretation, and antibiotic resistance research without overstating findings from non-tuberculosis models.
Carbapenemase Gene Dynamics in CREC, China
2026-10-07
Chen et al. map carbapenemase-encoding genes in 54 carbapenem-resistant Enterobacter cloacae isolates from eight teaching hospitals in Guangdong, highlighting plasmid-associated blaNDM-1, multidrug resistance, and frequent transfer potential. The study provides a useful molecular-epidemiology framework, while its hospital-based sampling and typing methods limit conclusions about wider regional transmission.